You are here

  1. Home
  2. Jenkins, R.

Jenkins, R.

"Value for money" in treating Alzheimer's disease with the new cholinesterase inhibitors

The absolute number of dementia cases is likely to increase due to the impending demographic changes. Several cost-of-illness studies of Alzheimer's disease, mainly from a societal perspective in developed countries, have demonstrated a huge economic burden. A substantial component of this huge economic burden is the direct costs of institutionalization and the indirect cost incurred by informal carers. This huge economic burden is of great interest because of the emergence of several cholinesterase inhibitors with proven efficacy in the treatment of Alzheimer's disease.

Thu, 07/20/2017 - 15:17